\nSchr\u00f6dinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational strategies, execute sophisticated molecular discovery workflows and interpret results. By combining AI with physics-based simulation, Bunsen allows researchers to apply their expertise at greater scale, enabling them to explore more scientific possibilities, prioritize the most promising opportunities with greater confidence and accelerate discovery decisions.<\/p>\n
\nAdvances in computer-aided drug discovery have expanded what researchers can model and simulate, but the complexity of designing, executing and interpreting those studies has grown alongside it. Built for molecular discovery, Bunsen was designed specifically to address that challenge. Unlike general-purpose AI systems that only retrieve and summarize existing scientific information, Bunsen is optimized to execute Schr\u00f6dinger’s validated computational methods and leverages decades of the company\u2019s physics-based molecular discovery expertise. With Bunsen, researchers can now evaluate more hypotheses, explore chemical space more efficiently and make higher-confidence decisions before compounds move into experimental testing. This helps computational chemists run concurrent research sessions and accomplish more across multiple programs. At the same time, Bunsen makes advanced computational methods accessible to experienced drug hunters who are not computational chemists.<\/p>\n
\n\u201cIn an era where computation is fundamentally changing molecular discovery, Bunsen expands what research teams can accomplish,\u201d said Ramy Farid, Ph.D., president and CEO of Schr\u00f6dinger. \u201cBunsen removes friction from the discovery cycle, enabling greater throughput and expanding the user base for our computational platform. As our customers accelerate their discovery timelines, our throughput-based licensing model is ideally suited to capture the value of this expanding utilization.\u201d<\/p>\n
\nOperating Bunsen requires a computing ecosystem capable of supporting large-scale molecular discovery. As part of Schr\u00f6dinger’s long-standing collaborations with NVIDIA and Google Cloud, both companies will provide a co-engineered full stack AI platform to support early Bunsen customers, helping research organizations scale their use of the platform across discovery programs. The collaboration also includes Google Cloud’s elastic computing infrastructure and the ability to integrate Schr\u00f6dinger’s platform with the NVIDIA BioNeMo\u2122 Agent Toolkit and the NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs.<\/p>\n
\n\u201cThe future of AI in scientific applications will be defined by agentic AI capable of planning and executing sophisticated, accurate computational workflows,\u201d said Anthony Costa, director of Digital Biology, NVIDIA. \u201cThe ability to integrate Schr\u00f6dinger’s platform with the NVIDIA BioNeMo Agent Toolkit and NVIDIA accelerated computing technologies demonstrates how agentic AI can help researchers apply advanced computational methods more effectively across molecular discovery.\u201d<\/p>\n
\n\u201cThe most ambitious molecular discovery programs require the ability to rapidly scale scientific computing,\u201d said Shweta Maniar, global director, Life Sciences Strategy & Solutions, Google Cloud. \u201cWe’re excited to expand our collaboration with Schr\u00f6dinger through this customer program. By providing access to the NVIDIA Blackwell platform on Google Cloud to early Bunsen customers, we’re helping research organizations realize the potential of leveraging physics combined with agentic AI to expand the scale and use of computation in discovery programs – and accelerate scientific progress.\u201d<\/p>\n
\nBunsen supports scientists throughout the discovery workflow by helping them:<\/p>\n
Understand – <\/b>Interprets scientific objectives, project context and research intent before recommending a computational approach.<\/p>\n Plan – <\/b>Develops a computational strategy designed to answer the scientific question before calculations begin.<\/p>\n Execute – <\/b>Orchestrates sophisticated computational workflows across the Schr\u00f6dinger platform.<\/p>\n Interpret – <\/b>Transforms computational results into actionable scientific insight.<\/p>\n \nBunsen is named in honor of pioneering chemist Robert Bunsen, whose contributions to experimental chemistry helped shape modern scientific research. The name reflects Schr\u00f6dinger’s commitment to furthering the advancement of molecular discovery.<\/p>\n \nThe early access version of Bunsen is now available to select customers, with full commercial release expected by the end of 2026.<\/p>\n About Schr\u00f6dinger<\/b><\/p>\n \nSchr\u00f6dinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schr\u00f6dinger\u2019s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schr\u00f6dinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. To learn more, visit www.schrodinger.com<\/a>, follow us on LinkedIn<\/a>, or visit our blog, Extrapolations.com<\/a>.<\/p>\n Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n \nThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 including, but not limited to those statements regarding the potential advantages of Schr\u00f6dinger\u2019s computational platform, including the capabilities and potential advantages of the early access version of Bunsen, its agentic AI co-scientist, expectations relating to the use of Bunsen by early customers, the adoption of Bunsen by research organizations following full commercial release, and researchers\u2019 ability to utilize a co-engineered full stack AI platform provided by NVIDIA and Google Cloud with Bunsen to scale their use of the platform. Statements including words such as \u201caim,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and statements in the future tense are forward-looking statements. These forward-looking statements reflect Schr\u00f6dinger\u2019s current views about its plans, intentions, expectations, strategies and prospects, which are based on the information currently available to the company and on assumptions the company has made. Actual results may differ materially from those described in these forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and important factors that are beyond Schr\u00f6dinger\u2019s control, including its ability to further develop its computational platform, its reliance on third-party providers of cloud-based infrastructures to host its software solutions, and the ability to retain and hire key personnel on its business and other risks detailed under the caption \u201cRisk Factors\u201d and elsewhere in the company\u2019s Securities and Exchange Commission filings and reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, as well as future filings and reports by the company. Any forward-looking statements contained in this press release speak only as of the date hereof. Except as required by law, Schr\u00f6dinger undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events, changes in expectations or otherwise.<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260727068879\/en\/<\/a><\/span><\/p>\n Jaren Madden (Investors and Media) Matthew Luchini (Investors) Theresa Masnik (Media) KEYWORDS:<\/b> New York United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Technology Research Clinical Trials Software Biotechnology Health Pharmaceutical Science Artificial Intelligence<\/p>\n\n
\n
\n
\n
<\/p>\n
\n<\/b>
Schr\u00f6dinger, Inc.
\n<\/b>
jaren.madden@schrodinger.com
\n<\/a>
617-286-6264<\/p>\n
\n<\/b>
Schr\u00f6dinger, Inc.
\n<\/b>
matthew.luchini@schrodinger.com
\n<\/a>
917-719-0636<\/p>\n
\n<\/b>
SHIFT Communications
\n<\/b>
schrodingerpr@shiftcomm.com
\n<\/a>
508-395-7416<\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260727068879\/en\/1376196\/3\/New_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n